ASX Health Stocks: Optiscan reveals new breakthrough on remote pathology technology

Optiscan to showcase its innovative cloud-based telepathology platform
dorsaVi seals crucial contracts across different sectors

Optiscan completes beta testing of breakthrough technology

Optiscan Imaging (ASX:OIL), in partnership with Prolucid Technologies, has successfully completed the beta testing phase for their innovative cloud-based telepathology platform.

This new system marks a significant advancement in the field of digital pathology by enabling real-time remote collaboration on patient imaging.

The beta testing demonstrated that the platform effectively supports device registration, authentication, and secure cloud connectivity.

This will enable medical devices to seamlessly transmit high-quality images to the cloud as they are captured, allowing pathologists and clinicians to collaborate instantly regardless of their location.

The platform leverages Optiscan’s advanced confocal imaging technology, which generates detailed digital pathology data.

The telepathology platform also features a dedicated web portal for accessing and interacting with the imaging data.

This ensures that all transmitted data is securely encrypted and that patient privacy is upheld, meeting the highest regulatory and cybersecurity standards.

Additionally, the system supports offline review and annotation of images, with future updates planned to include detailed reporting capabilities.

Optiscan believes the breakthrough has the potential to transform how pathology services are delivered, particularly in remote and underserved areas where access to specialised expertise is limited.

Dr Camile Farah, CEO and Managing Director of Optiscan, said he was thrilled with the outcomes from the beta phase testing, acknowledging the crucial role of the company’s partner, Prolucid Technologies, in achieving this milestone.

Dr Farah explained that in the past, regional, rural and remote health facilities have lacked the dedicated pathology expertise, limiting collaboration and immediate decision-making between clinicians and pathologists.

“Our platform provides a way for isolated communities to tap into pathology expertise previously not available to them due to limited medical infrastructure or difficulties in attracting health care professionals.

“Our telepathology-enabled imaging solutions democratise pathology services and high quality patient care,” said Dr Farah.

dorsaVi seals contracts across mining, healthcare, shipping

Meanwhile, dorsaVi (ASX:DVL), a leader in human movement analytics and developer of FDA-approved wearable sensors, has secured new contracts worth approximately $110,000.

These deals came through a commercial agreement with one of Australia’s leading insurers and involve prominent Australian companies in the mining, healthcare, and shipping sectors.

The contracts, which are set to be fulfilled between the fourth quarter of FY24 and the first quarter of FY25, will see dorsaVi applying its expertise in musculoskeletal risk analysis to improve workplace safety.

For the mining sector, dorsaVi will collaborate with a major mining group in Western Australia to use wearable sensors and video analysis to identify and mitigate injury risks specific to mining roles.

In healthcare, the company will work with a leading provider to assess non-clinical hospital roles, focusing on high-risk manual handling tasks and developing strategies to reduce workplace injuries.

In the shipping sector, dorsaVi’s video AI algorithms will be used by a major container terminal operator to analyse and manage movement risks associated with securing shipping containers.

Dr. Andrew Ronchi, dorsaVi’s CEO, said these contracts expand the company’s work on preventing musculoskeletal injuries.

“These new customer wins represent an exciting expansion of our work on preventing musculoskeletal injuries using wearable sensors and video algorithms and validates our technology and commercialisation strategy,” he said.

At Stockhead we tell it like it is. While Optiscan Imaging is a Stockhead advertiser, it did not sponsor this article.